Introduction {#s1}
============

GPIHBP1, a GPI-anchored protein of capillary endothelial cells, is required for lipoprotein lipase (LPL)--mediated processing of triglyceride-rich lipoproteins (TRLs) ([@bib7]). The principal function of GPIHBP1 is to capture LPL within the interstitial spaces, where it is secreted by parenchymal cells, and then to shuttle this enzyme to the luminal surface of capillary endothelial cells ([@bib18]). GPIHBP1 is a long-lived protein ([@bib87]; [@bib61]) that moves bidirectionally across endothelial cells, with each trip to the abluminal plasma membrane representing an opportunity to capture LPL and bring it to the capillary lumen ([@bib19]). When GPIHBP1 is absent or defective, LPL is stranded within the interstitial spaces, where it remains bound to sulfated proteoglycans near the surface of cells ([@bib87]; [@bib18]; [@bib4]; [@bib23]). The inability of LPL to reach the capillary lumen in the absence of GPIHBP1 expression profoundly impairs TRL processing, resulting in severe hypertriglyceridemia (chylomicronemia) ([@bib7]; [@bib18]; [@bib27]).

GPIHBP1 is expressed in the capillary endothelial cells of peripheral tissues, with particularly high levels of expression in heart and brown adipose tissue ([@bib7]; [@bib18]; [@bib23]). Most of the LPL within those tissues is bound to GPIHBP1 on capillaries ([@bib7]; [@bib18]; [@bib19]; [@bib4]; [@bib23]; [@bib5]; [@bib3]), and the processing of TRLs in these tissues is robust, generating fatty acid nutrients for nearby parenchymal cells ([@bib23]; [@bib43]; [@bib37]). By contrast, GPIHBP1 is absent from capillaries of the brain ([@bib87]; [@bib18]; [@bib61]), a tissue that depends on glucose for fuel ([@bib57]). When wild-type mice are injected intravenously with a GPIHBP1-specific antibody, the antibody rapidly binds to GPIHBP1-expressing capillaries in peripheral tissues and disappears from the plasma ([@bib18]; [@bib61]). By contrast, there is no antibody binding to the capillaries of the brain ([@bib18]; [@bib61]).

For the lipolytic processing of TRLs to proceed, lipoproteins in the bloodstream must marginate along the luminal surface of capillaries ([@bib27]). TRL margination along capillaries depends on GPIHBP1, more specifically on GPIHBP1-bound LPL ([@bib27]). In GPIHBP1-deficient mice, TRLs never stop along heart capillaries and instead simply 'flow on by' in the bloodstream ([@bib27]). In wild-type mice, TRLs marginate along heart capillaries, but TRL margination is absent along capillaries of the brain ([@bib27]).

Even though GPIHBP1 is not found in brain capillaries, there is ample evidence for LPL expression within the brain ([@bib9]; [@bib10]; [@bib25]; [@bib80]; [@bib86]; [@bib22]). Several groups have found LPL in the rat brain, specifically in neurons of the dentate gyrus and hippocampus, in pyramidal cells of the cortex, and in Purkinje cells of the cerebellum ([@bib9]; [@bib10]; [@bib25]; [@bib80]; [@bib22]). Using single-cell RNA sequencing, [@bib91] found *Lpl* transcripts in the resident macrophages of the brain (microglia), with lower levels in astrocytes, neurons, and oligodendrocytes. Using the same approach, [@bib78] found LPL expression in brain smooth muscle cells and in perivascular fibroblasts (at even higher levels than in microglial cells). Given the absence of GPIHBP1 expression in brain capillaries and the absence of TRL margination along brain capillaries, we have proposed that the LPL in the brain probably has an extravascular function, presumably to hydrolyze glycerolipids within the extracellular spaces ([@bib87]; [@bib1]).

Despite the absence of GPIHBP1 expression in brain capillaries, we were curious about whether GPIHBP1 might be expressed in the capillaries of gliomas. Glioma capillaries are morphologically distinct from normal brain capillaries ([@bib88]; [@bib41]; [@bib58]; [@bib11]), and the blood--brain barrier is often defective ([@bib90]). Electron microscopy has suggested that glioblastoma capillaries resemble capillaries in peripheral tissues ([@bib79]).

If GPIHBP1 were to be expressed in glioma capillaries, it could be relevant to glioma metabolism. The GPIHBP1 might capture locally produced LPL, allowing for TRL margination and TRL processing, and thereby providing a source of lipid nutrients for glioma cells. Interestingly, [@bib20] documented LPL expression in gliomas. Also, several studies have raised the possibility that glioma cells use fatty acids for fuel ([@bib51]; [@bib30]; [@bib28]; [@bib29]; [@bib31]) and that levels of free fatty acids are higher in gliomas than in normal brain tissue ([@bib31]; [@bib26]).

In the current study, we sought to determine whether glioma capillaries express GPIHBP1 and, if so, whether it binds LPL and facilitates TRL margination and the lipolytic processing of TRLs. In our study, we took advantage of NanoSIMS imaging, a high-resolution mass spectrometry--based imaging modality that makes it possible to visualize TRL margination and TRL processing in tissue sections ([@bib37]; [@bib43]; [@bib44]; [@bib35]; [@bib36]; [@bib38]; [@bib39]). This imaging modality allowed us to visualize TRL margination in glioma capillaries as well as the entry of TRL-derived nutrients into tumor cells.

Results {#s2}
=======

GPIHBP1 is expressed in the endothelial cells of human gliomas {#s2-1}
--------------------------------------------------------------

We sectioned 20 human gliomas ([Table 1](#table1){ref-type="table"}) and screened them for GPIHBP1 expression by confocal microscopy with three GPIHBP1-specific monoclonal antibodies (mAbs) --- RF4, which binds to residues 27--44 downstream from GPIHBP1's acidic domain ([@bib48]); and RE3 and RG3, which both bind to GPIHBP1's LU (Ly6/uPAR) domain ([@bib42]). GPIHBP1 in capillary endothelial cells was detected in 14 of 20 gliomas ([Table 1](#table1){ref-type="table"}) and colocalized with von Willebrand factor, an endothelial cell marker ([Figure 1](#fig1){ref-type="fig"}). GPIHBP1 expression in glioma capillaries did not appear to correlate with glioma grade, 1p/19q co-deletions, or IDH1 mutations ([Table 1](#table1){ref-type="table"}). GPIHBP1 was not detectable in the capillaries of human brain specimens ([Figure 1](#fig1){ref-type="fig"}). The GPIHBP1 in glioma capillaries could be detected with all three GPIHBP1-specific mAbs ([Figure 2A](#fig2){ref-type="fig"}). To be confident in the specificity of the antibodies, we performed studies in which recombinant human GPIHBP1 was added to the GPIHBP1-specific mAbs before incubating the solution with the glioma sections. As expected, the presence of recombinant GPIHBP1 eliminated binding of the GPIHBP1-specific mAbs to glioma capillaries ([Figure 2B](#fig2){ref-type="fig"}). GPIHBP1 expression in glioma capillaries could also be detected by immunoperoxidase staining ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}).

![GPIHBP1 expression in the endothelial cells of several human gliomas.\
Immunohistochemical studies on surgically resected gliomas (Gliomas 1, 5, 9; [Table 1](#table1){ref-type="table"}) and non-diseased human frontal lobe (n = 3), revealing GPIHBP1 expression in capillaries of gliomas but not in frontal lobe specimens. GPIHBP1 (detected with a combination of the mAbs RE3 and RF4, 10 μg/ml each \[red\]) colocalized with von Willebrand factor (vWF, a marker for endothelial cells \[green\]), but not with glial fibrillary acidic protein (GFAP, a marker for astroglial cells \[magenta\]). DNA was stained with DAPI (blue). Three sections of each tumor and normal brain were evaluated and representative images are shown. Scale bar, 50 μm.](elife-47178-fig1){#fig1}

![Detecting GPIHBP1 in capillaries of human glioma specimens with three different monoclonal antibodies (mAbs) against GPIHBP1.\
(**A**) Confocal fluorescence microscopy studies on sections from glioma sample 1 ([Table 1](#table1){ref-type="table"}), demonstrating the detection of GPIHBP1 with three different human GPIHBP1--specific monoclonal antibodies (mAbs). Tissue sections were fixed with 3% PFA and then stained with mAbs against human GPIHBP1 (RF4, RE3, or RG3, 10 μg/ml \[red\]), an antibody against von Willebrand factor (vWF\[green\]), and an antibody against glial fibrillary acidic protein (GFAP \[magenta\]). All three GPIHBP1-specific mAbs detected GPIHBP1 in capillaries, colocalizing with von Willebrand factor. DNA was stained with DAPI (blue). Scale bar, 50 μm. (**B**) Immunofluorescence confocal microscopy studies on human glioma sample 5, performed with mAbs RF4 and RE3 (10 μg/ml) in the presence or absence of 50 μg of recombinant soluble human GPIHBP1 (hGPIHBP1). Adding recombinant hGPIHBP1 to the antibody incubation abolished binding of the GPIHBP1-specific mAbs to GPIHBP1 on glioma capillaries. Images show GPIHBP1 (red), vWF (green), GFAP (magenta), and DAPI (blue). Three sections of tumors were evaluated; representative images are shown. Scale bar, 50 μm.](elife-47178-fig2){#fig2}
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###### Human glioma tumor specimens.

Expression of GPIHBP1 was assessed by immunohistochemistry with mAbs against human GPIHBP1 (RF4, RE3, RG3). Those conducting the studies were blinded to diagnoses. This table details the tumor diagnosis, location, 1p/19q co-deletion, and IDH1 mutation status, as well as the presence of GPIHBP1.

  Sample ID   Tissue diagnosis                             Location                                          1p/19q co-deletion   IDH1 mutation   GPIHBP1
  ----------- -------------------------------------------- ------------------------------------------------- -------------------- --------------- ---------
  1           Glioblastoma (GBM)                           Right frontal, parietal                           No                   Negative        Yes
  2           GBM                                          Left temporal                                     No                   Negative        Yes
  3           GBM                                          Right occipital                                   No                   Negative        Yes
  4           GBM                                          Left frontal                                      No                   Negative        Yes
  5           Oligodendroglioma Grade II                   Left anterior temporal, left posterior temporal   Yes                  Negative        Yes
  6           Oligoastrocytoma Grade III                   Right temporal                                    No                   Negative        Yes
  7           GBM + oligodendroglial component             Left frontal                                      Yes                  Negative        Yes
  8           GBM + extensive oligodendroglial component   Right frontal                                     No                   Negative        Yes
  9           Oligodendroglioma Grade III                  Left frontal                                      Yes                  +R132H          Yes
  10          Oligodendroglioma Grade III                  Left frontal                                      Yes                  +R132H          Yes
  11          Oligoastrocytoma                             Right parietal                                    No                   Negative        Yes
  12          Oligodendroglioma Grade III                  Right parietal                                    Yes                  +R132H          Yes
  13          Oligodendroglioma Grade III                  Right parietal                                    Yes                  Negative        Yes
  14          Oligoastrocytoma Grade III                   Left temporal                                     No                   +R132H          Yes
  15          Oligoastrocytoma Grade III                   Right temporal                                    No                   +R132G          No
  16          Oligoastrocytoma Grade III                   Right frontal                                     No                   +R132H          No
  17          Oligodendroglioma Grade III                  Left frontal                                      Yes                  Negative        No
  18          Oligodendroglioma Grade III                  Left frontal                                      Yes                  +R132H          No
  19          Oligodendroglioma Grade III                  Left temporal                                     Yes                  Negative        No
  20          Oligodendroglioma Grade III                  Right temporal                                    Yes                  +R132H          No

GPIHBP1 is present in the capillary endothelial cells of mouse gliomas {#s2-2}
----------------------------------------------------------------------

To determine whether GPIHBP1 is expressed in a mouse model of glioblastoma, spheroids of syngeneic C57BL/6 mouse CT-2A glioma cells ([@bib72]; [@bib60]), modified to express a blue fluorescent protein (BFP) ([@bib56]), were engrafted into the brains of mice harboring an endothelial cell--specific Pdgfb-iCreER^T2^ transgene ([@bib14]) and a ROSA^mT/mG^ reporter allele ([@bib59]). ROSA^mT/mG^ is a two-color fluorescent, membrane-targeted Cre-dependent reporter allele. In the absence of Cre, all cells express a membrane-localized tdTomato and fluoresce red. In the setting of Cre expression, cells express membrane-localized EGFP (rather than tdTomato) and fluoresce green. Before tumor implantation, mice were injected with tamoxifen to induce Pdgfb-driven Cre expression in endothelial cells; thus, the endothelial cells of the mice expressed EGFP and fluoresced green. Mice harboring gliomas (after three weeks of growth) were injected intravenously with an Alexa Fluor 647--conjugated antibody against mouse GPIHBP1 (11A12) ([@bib8]). Mice were perfused with PBS and then perfusion-fixed with 2% PFA, and tumor sections were processed for confocal immunofluorescence microscopy. GPIHBP1 was detected in endothelial cells of the gliomas, colocalizing with EGFP (brain endothelial cells), but GPIHBP1 was absent from capillaries in the adjacent normal brain ([Figure 3](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). Using transmission electron microscopy, we observed large and irregularly shaped capillaries in gliomas, with numerous villus-like structures on the luminal surface of endothelial cells ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}), similar to findings reported for capillaries in human gliomas ([@bib79]; [@bib15]; [@bib84]).

![GPIHBP1 is expressed by capillary endothelial cells in mouse gliomas.\
Confocal microscopy images of a BFP-tagged CT-2A glioma implanted in a ROSA^mT/mG^::*Pdgfb-iCreER^T2^* mouse, revealing the expression of GPIHBP1 in capillary endothelial cells of the glioma but not those of normal brain. Tamoxifen was administered prior to implantation of the glioma spheroid to activate membrane-targeted EGFP in endothelial cells (green). After three weeks of glioma growth, mice were anesthetized and injected via the tail vein with an Alexa Fluor 647--labeled antibody against mouse GPIHBP1 (11A12; red). The mice were then perfused with PBS and perfusion-fixed with 2% PFA in PBS. Glioma and adjacent normal brain were harvested, and 200-μm-thick sections were imaged by confocal microscopy. GPIHBP1 was present on endothelial cells of the glioma (blue) but was absent from normal brain. High-magnification images of the boxed area are shown on the right. Three mice were evaluated; representative images are shown. Scale bar, 50 μm.](elife-47178-fig3){#fig3}

The factors that regulate *Gpihbp1* expression in the capillary endothelial cells of peripheral tissues and gliomas are incompletely understood. However, a recent study found that *Gpihbp1* transcript levels in rat aortic endothelial cells are upregulated by vascular endothelial growth factor (VEGF) ([@bib12]), an angiogenic factor known to be expressed at high levels by glioma cells ([@bib65]; [@bib64]; [@bib13]). We found that *Gpihbp1* expression in the mouse brain endothelial cell line bEnd.3 is upregulated by recombinant VEGF ([Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}).

GLUT1 is expressed in the capillaries of gliomas and normal brain {#s2-3}
-----------------------------------------------------------------

We used immunofluorescence microscopy to examine the expression of GPIHBP1 and GLUT1 (the main glucose transporter in brain capillaries \[[@bib52]; [@bib63]\]) in mouse gliomas and adjacent normal brain. GPIHBP1 expression was detected in gliomas but was absent in the normal brain. The signal for GLUT1 was strong in the endothelial cells of the normal brain and was easily detectable in the capillaries of gliomas ([Figure 4](#fig4){ref-type="fig"}, [Figure 4---figure supplements 1](#fig4s1){ref-type="fig"}--[2](#fig4s2){ref-type="fig"}). Consistent findings were observed in single-cell RNA-seq studies on vascular cells of gliomas (Ken Matsumoto, manuscript in preparation) and normal brain vascular cells ([@bib78]; [@bib40]). Endothelial cells of gliomas (identifed by high von Willebrand factor \[vWF\] expression) exhibit high expression of *Gpihbp1* and somewhat lower levels of *Glut1* expression (e.g., Endothelial cell cluster 5 in [Figure 4---figure supplement 3](#fig4s3){ref-type="fig"}). In normal brain, *Glut1* was highly expressed in endothelial cells, whereas *Gpihbp1* expression was absent ([Figure 4---figure supplement 3](#fig4s3){ref-type="fig"}). In *Gpihbp1*-deficient mice, GLUT1 expression was detectable in the capillaries of gliomas and normal brain ([Figure 4---figure supplement 4](#fig4s4){ref-type="fig"}).

![Expression of GPIHBP1 and GLUT1 in the endothelial cells of mouse gliomas.\
Immunohistochemical studies of a BFP-expressing CT-2A glioma (after three weeks of growth). Mice were injected *via* the tail vein with an Alexa Fluor 647--labeled antibody against mouse GPIHBP1 (11A12; green), then perfused with PBS and perfusion-fixed with 2% PFA. Glioma and adjacent normal brain tissue were harvested, then 200-μm thick sections cut, fixed with 4% PFA, and stained with an antibody against GLUT1 (red). GPIHBP1 was present in the capillaries of mouse gliomas (blue) but absent from the capillaries of the normal brain. High-magnification images in the boxed region are shown below. Three mice were evaluated; representative images are shown. Scale bar, 50 μm.](elife-47178-fig4){#fig4}

LPL is present on GPIHBP1-expressing capillaries of mouse gliomas {#s2-4}
-----------------------------------------------------------------

Most of the LPL in peripheral tissues (e.g., heart or brown adipose tissue) is bound to GPIHBP1 on capillaries; consequently, LPL and GPIHBP1 colocalize in tissue sections ([@bib87]; [@bib18]; [@bib19]; [@bib4]; [@bib23]; [@bib5]; [@bib3]). We hypothesized that GPIHBP1-expressing endothelial cells of gliomas could capture LPL. Several observations prompted us to consider this hypothesis. First, as noted earlier, there is ample evidence for LPL expression in the brain ([@bib9]; [@bib10]; [@bib25]; [@bib80]; [@bib86]; [@bib91]), and it seemed reasonable that some of that LPL would reach high-affinity GPIHBP1-binding sites on endothelial cells. Second, gliomas contain large numbers of macrophages (F4/80-expressing cells; [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}), and macrophages are known to express LPL ([@bib53]). We found that LPL could be detected in peritoneal macrophages from wild-type mice but not in macrophages harvested from *Lpl^--/--^* mice carrying a skeletal muscle--specific human LPL transgene (*Lpl^--/--^*MCK-hLPL) ([@bib49]) ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}). We also found that LPL could be detected in some of the macrophages in mouse gliomas and in normal brain of wild-type mice, but not in the brain of *Lpl^--/--^*MCK-hLPL mice ([Figure 5---figure supplement 3](#fig5s3){ref-type="fig"}). These findings were consistent with single-cell RNA-seq data from glioma and normal brain, in which *Lpl* transcripts were found in the macrophages of gliomas and microglia of normal brain ([Figure 4---figure supplement 3](#fig4s3){ref-type="fig"}). *Lpl* transcripts are not present in capillary endothelial cells. Third, the most highly upregulated fatty acid metabolism gene in human gliomas, compared to normal brain tissue, is *LPL* ([Figure 5---figure supplement 4](#fig5s4){ref-type="fig"}). The second most perturbed gene in gliomas is CD36, which encodes a putative fatty acid transporter ([Figure 5---figure supplement 4](#fig5s4){ref-type="fig"}).

To determine whether LPL is bound to GPIHBP1-expressing capillaries of gliomas, we performed immunohistochemical studies, taking advantage of an affinity-purified goat antibody against mouse LPL ([@bib62]). These studies revealed colocalization of GPIHBP1 and LPL in glioma capillaries ([Figure 5](#fig5){ref-type="fig"}, [Figure 5---figure supplement 5](#fig5s5){ref-type="fig"}). LPL was not present in the capillaries of the normal brain or in the capillaries of gliomas from *Gpihbp1^--/--^* mice ([Figure 5](#fig5){ref-type="fig"}, [Figure 5---figure supplement 5](#fig5s5){ref-type="fig"}). As expected, the binding of the goat LPL antibody to tissues of *Lpl^--/--^*MCK-hLPL mice was low ([Figure 5](#fig5){ref-type="fig"}, [Figure 5---figure supplement 5](#fig5s5){ref-type="fig"}), whereas mouse LPL was easily detectable in the heart capillaries of wild-type mice (colocalizing with GPIHBP1) ([Figure 5---figure supplement 6](#fig5s6){ref-type="fig"}). Consistent with earlier publications ([@bib9]; [@bib80]), we observed a strong mouse LPL signal in the hippocampal neurons of wild-type mice but not of *Lpl^--/--^*MCK-hLPL mice ([Figure 5---figure supplement 7](#fig5s7){ref-type="fig"}). Of note, LPL was undetectable in 'secondary antibody--only' experiments (i.e., when the incubation of the primary antibody with tissue sections was omitted) ([Figure 5](#fig5){ref-type="fig"}, [Figure 5---figure supplement 5](#fig5s5){ref-type="fig"}--[7](#fig5s7){ref-type="fig"}).

![Lipoprotein lipase (LPL) colocalizes with GPIHBP1 in glioma capillaries.\
Confocal immunofluorescence microscopy studies on glioma and normal brain from wild-type and *Gpihbp1^--/-- ^*mice, along with the brain from an *Lpl^--/--^* mouse carrying a skeletal muscle--specific human LPL transgene (MCK). Glioma and brain sections (10-μm-thick) were fixed with 3% PFA and then stained with a mAb against mouse GPIHBP1 (11A12; green), a goat antibody against mouse LPL (red), and a rabbit antibody against CD31 (white). LPL colocalizes with GPIHBP1 and CD31 in the capillaries of gliomas; GPIHBP1 and LPL were absent from normal brain capillaries and from glioma capillaries in *Gpihbp1^--/--^* mice. DNA was stained with DAPI (blue). No LPL was detected in the capillaries of *Lpl*-deficient mice (MCK) or when the incubation with primary antibodies was omitted (Secondary Only). Staining of all tissue sections was performed simultaneously, and all images were recorded with identical microscopy settings. Three mice per genotype were evaluated; representative images are shown. Scale bar, 50 μm.](elife-47178-fig5){#fig5}

There is little reason to suspect that the expression of LPL influences the expression of GPIHBP1 in capillaries. The overexpression of human LPL in the skeletal muscle of *Lpl^--/--^*MCK-hLPL mice did not alter levels of *Gpihbp1* expression ([Figure 5---figure supplement 8](#fig5s8){ref-type="fig"}).

Margination of TRLs along glioma capillaries and uptake of TRL-derived nutrients in glioma cells {#s2-5}
------------------------------------------------------------------------------------------------

Given the presence of GPIHBP1-bound LPL on glioma capillaries, we suspected that we might find evidence of TRL margination and processing in gliomas. To test this idea, TRLs that were heavily labeled with deuterated lipids (\[^2^H\]TRLs) ([@bib37]) were injected intravenously into mice harboring CT-2A gliomas (after three weeks of glioma growth). After allowing the \[^2^H\]TRLs to circulate for either 1 min or 30 min, the mice were euthanized, extensively perfused with PBS, and perfusion-fixed with carbodiimide/glutaraldehyde. Heart, brain, and glioma specimens were harvested and processed for NanoSIMS imaging. ^12^C^14^N^--^ or ^1^H^--^ images were used to visualize tissue morphology, and ^2^H/^1^H images were used to identify regions of ^2^H enrichment. The scale in the ^2^H/^1^H images of brain and glioma specimens ranges from 0.00018 to 0.0003 (i.e., from levels slightly above ^2^H natural abundance to levels twice as high as ^2^H natural abundance). The scale in the heart ^2^H/^1^H images ranges from 0.00018 to 0.0006. In mice euthanized 1 min after the \[^2^H\]TRLs injection, \[^2^H\]TRL margination was visualized along the luminal surface of glioma and heart capillaries, but not along the capillaries of normal brain ([Figure 6A--B](#fig6){ref-type="fig"}). After 1 min, deuterated lipids from the \[^2^H\]TRLs had already entered glioma cells and were even found in cytosolic neutral lipid droplets of those cells ([Figure 6B](#fig6){ref-type="fig"}). By contrast, ^2^H enrichment was virtually absent in normal brain. As expected ([@bib37]), we observed substantial amounts of \[^2^H\]TRL-derived lipids in cardiomyocytes, including in cytosolic lipid droplets. In gliomas harvested 30 min after the injection of \[^2^H\]TRLs, we observed similar findings: TRL margination along capillaries of gliomas and heart and the uptake of TRL-derived nutrients by glioma cells and cardiomyocytes ([Figure 7](#fig7){ref-type="fig"}). Again, \[^2^H\]TRL margination was absent in capillaries of the normal brain at the 30-min time point, and we did not find ^2^H enrichment in the parenchymal cells of the normal brain. We did, however, observe very low levels of ^2^H enrichment in capillary endothelial cells of normal brain. Given the absence of TRL margination in normal brain capillaries, we speculate that the very low amounts of ^2^H enrichment in brain capillary endothelial cells may relate to \[^2^H\]TRL processing in the periphery, followed by the uptake of unesterified \[^2^H\]fatty acids by endothelial cells of the brain.

![NanoSIMS imaging reveals margination of \[^2^H\]TRLs along glioma capillaries and ^2^H enrichment in adjacent glioma cells.\
Four-month-old C57BL/6 mice harboring CT-2A gliomas were fasted for 4 hr and then injected intravenously with 200 μl of \[^2^H\]TRLs. After 1 min, mice were euthanized and perfusion-fixed with carbodiimide/glutaraldehyde. Tissue sections were processed for NanoSIMS imaging. (**A**) NanoSIMS images showing margination of \[^2^H\]TRLs in glioma capillaries. ^1^H^--^ images were created to visualize tissue morphology (upper panels). Composite ^2^H/^1^H (red) and ^1^H^--^ (blue) images reveal \[^2^H\]TRLs (white arrows) in glioma and heart capillaries (middle and lower panels). The lower panels are close-up images of the regions outlined in the middle panels. ^2^H/^1^H ratio scales were set to show marginated TRLs. Scale bars, 4 μm. (**B**) NanoSIMS images showing ^2^H enrichment in glioma tissue. ^12^C^14^N^--^ images were generated to visualize tissue morphology. ^2^H/^1^H ratio images reveal margination of \[^2^H\]TRLs within the capillary lumen and ^2^H-enriched lipid droplets in gliomas and heart. There was no ^2^H enrichment in normal brain tissue. Scale bars, 4 μm. The bar graph shows the average fold change ± SD in the ^2^H/^1^H ratio above natural abundance. The experiment was performed in two mice with a minimum of seven images analyzed for each sample. Differences were assessed using a Student's *t*-test with Welch's correction.](elife-47178-fig6){#fig6}

![NanoSIMS imaging showing ^2^H enrichment in gliomas 30 min after an intravenous injection of \[^2^H\]TRLs.\
Four-month-old C57BL/6 mice harboring CT-2A gliomas were fasted for 4 hr and then injected intravenously with 200 μl of \[^2^H\]TRLs. After 30 min, mice were euthanized and perfusion-fixed with carbodiimide/glutaraldehyde. Sections of glioma, brain, and heart were processed for NanoSIMS imaging. ^12^C^14^N^--^ images were created to visualize tissue morphology. ^2^H/^1^H ratio images reveal margination of \[^2^H\]TRLs along the capillary lumen (white arrows) and ^2^H enrichment in glioma and heart, including in cytosolic lipid droplets. Images of normal brain revealed slight ^2^H enrichment in capillary endothelial cells. Scale bars, 4 μm. The bar graph shows the average fold change ± SD in the ^2^H/^1^H ratio above natural abundance. The experiment was performed in two mice, with a minimum of seven images analyzed for each sample. Differences were assessed with a Student's *t*-test with Welch's correction.](elife-47178-fig7){#fig7}

At both the 1-min and 30-min time points, we observed heterogeneity in ^2^H enrichment in glioma cells, with occasional perivascular cells exhibiting striking ^2^H enrichment. We do not know the identity of the highly enriched perivascular cells (i.e., whether they are tumor cells, pericytes, or macrophages), nor do we understand why some cells within the glioma took up more \[^2^H\]TRL-derived lipids than other cells.

As an experimental control, we injected a mouse with PBS alone rather than with \[^2^H\]TRLs. As expected, there was no ^2^H enrichment in the tissues of that mouse ([Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}).

We performed an additional study in which \[^2^H\]TRLs were injected intravenously into a wild-type mouse and a *Gpihbp1^--/--^* mouse. After 15 min, the hearts and brains from these mice were harvested and processed for NanoSIMS imaging. The ^2^H/^1^H ratio images revealed ^2^H enrichment in the heart of the wild-type mouse but negligible ^2^H enrichment in the heart of the *Gpihbp1^--/--^* mouse (^2^H enrichment in cardiomyocyte lipid droplets was only \~10% greater than natural abundance) ([Figure 7---figure supplement 2](#fig7s2){ref-type="fig"}). In hindsight, the negligible amounts of ^2^H enrichment in the heart of the *Gpihbp1^--/--^* mouse was probably not surprising, given the very large pool of unlabeled triglycerides in the bloodstream of *Gpihbp1^--/--^* mice (\~50--100-fold higher than that in wild-type mice). At the 15-min time point, we were unable to detect ^2^H enrichment in the brain of either the wild-type mouse or the *Gpihbp1^--/--^* mouse ([Figure 7---figure supplement 2](#fig7s2){ref-type="fig"}).

^13^C enrichment in gliomas following administration of ^13^C-labeled fatty acids or ^13^C-labeled glucose by gastric gavage {#s2-6}
----------------------------------------------------------------------------------------------------------------------------

In addition to studies of gliomas after an intravenous injection of \[^2^H\]TRLs, we performed NanoSIMS imaging after administering ^13^C-labeled fatty acids or ^13^C-labeled glucose by gastric gavage (three doses over 36 hr) ([Figure 8](#fig8){ref-type="fig"}). In the case of the ^13^C-labeled fatty acid experiments, it is likely that most of the ^13^C-labeled lipids entered the bloodstream in chylomicrons. Once again, ^12^C^14^N^--^ images were useful for tissue morphology, and the ^13^C/^12^C ratio images were useful to identify regions of ^13^C enrichment. The scale for the ^13^C/^12^C images ranges from 0.0115 to 0.0150 (from slightly above ^13^C natural abundance to \~36% greater than natural abundance). After administering ^13^C-labeled fatty acids, ^13^C enrichment was observed in both glioma cells and in the capillary endothelial cells of gliomas ([Figure 8A](#fig8){ref-type="fig"}). In some images, ^13^C-enriched cytosolic lipid droplets were visible in glioma cells ([Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}). ^13^C enrichment was virtually absent from normal brain ([Figure 8A](#fig8){ref-type="fig"}). However, after adjusting the scale of the NanoSIMS images, a small amount of ^13^C enrichment was observed in capillary endothelial cells within the brain parenchyma ([Figure 8---figure supplement 2](#fig8s2){ref-type="fig"}). As expected ([@bib37]), we observed substantial amounts of ^13^C enrichment in cardiomyocytes ([Figure 8A](#fig8){ref-type="fig"}).

![Tissue uptake of fatty acid and glucose-derived nutrients by mice harboring CT-2A gliomas.\
(**A**) NanoSIMS images showing ^13^C enrichment in mouse tissues (brain, glioma, and heart) after oral administration of ^13^C-labeled mixed fatty acids to mice (three 80-mg doses administered 12 h apart). ^12^C^14^N^--^ images were generated to visualize tissue morphology; ^13^C/^12^C ratio images were used to visualize ^13^C enrichment in tissues. Scale bars, 4 μm. (**B**) NanoSIMS images revealing ^13^C enrichment in tissues following oral administration of ^13^C-labeled glucose to mice (three 75-mg doses given 12-h apart). ^12^C^14^N^--^ images were generated to visualize tissue morphology; ^13^C/^12^C ratio images were generated to assess ^13^C enrichment in tissues. Scale bars, 4 μm. The bar graphs show the average ^13^C/^12^C ratio ± SD multiplied by 10,000 for fatty acids (left) and glucose (right). Each experiment was performed in two mice, with a minimum of seven images analyzed for each sample. Differences were assessed using a Student's *t*-test with Welch's correction.](elife-47178-fig8){#fig8}

After administering \[^13^C\]glucose to mice, ^13^C enrichment was easily detectable in normal brain but was even \~20% higher in gliomas ([Figure 8B](#fig8){ref-type="fig"}). We also observed ^13^C enrichment in cardiomyocytes ([Figure 8B](#fig8){ref-type="fig"}). As expected, there was no ^13^C enrichment in the tissues of a mouse that was administered PBS alone ([Figure 8---figure supplement 3](#fig8s3){ref-type="fig"}).

To determine whether an absence of GPIHBP1 expression would influence the growth of glioma tumors, CT-2A glioma cells that had been stably transfected with a *Gaussia* luciferase reporter were injected into the brains of wild-type and *Gpihbp1^--/--^* mice (n = 11/group). Tumor burden was assessed in live animals by measuring luciferase activity in the blood ([@bib54]; [@bib77]). We observed no statistically significant differences in tumor growth, tumor size, or survival between wild-type and *Gpihbp1^--/--^* mice ([Figure 8---figure supplement 4](#fig8s4){ref-type="fig"}). This result was not particularly surprising, given that gliomas have a robust capacity to utilize glucose-derived nutrients ([Figure 8B](#fig8){ref-type="fig"}).

Discussion {#s3}
==========

We sought to determine whether GPIHBP1, despite its complete absence from the capillaries of the brain, might nevertheless be expressed in the capillaries of gliomas. Using standard immunohistochemistry procedures, we documented GPIHBP1 expression in capillary endothelial cells of human gliomas and CT-2A-derived mouse gliomas. The expression of GPIHBP1 in glioma capillaries was intriguing, but the crucial issue is whether LPL would be bound to the GPIHBP1. Additional immunohistochemistry studies on mouse gliomas revealed that LPL colocalizes with GPIHBP1 on glioma capillaries, just as LPL colocalizes with GPIHBP1 in the capillaries of heart and brown adipose tissue ([@bib87]; [@bib18]; [@bib19]; [@bib4]; [@bib23]; [@bib5]; [@bib3]). The binding of LPL to GPIHBP1 was specific: the LPL-specific goat antibody did not detect LPL in the capillaries of gliomas in *Gpihbp1*^--/--^ mice, nor did it detect any LPL in macrophages or hippocampal neurons of *Lpl^--/--^*MCK-hLPL mice. The colocalization of GPIHBP1 and LPL in the capillaries of gliomas implied that we might find evidence for TRL margination and processing in these tumors. Indeed, we observed both \[^2^H\]TRL margination along glioma capillaries and the entry of TRL-derived nutrients into glioma cells. Consistent with results of earlier studies ([@bib27]; [@bib37]), TRL margination was absent from the capillaries of normal brain, and we found no ^2^H enrichment in the brain parenchyma. We did, however, find very low levels of ^2^H enrichment in capillary endothelial cells of normal brain, perhaps as a result of the uptake of fatty acids that are derived from TRL processing in peripheral tissues. We observed consistent findings after administering \[^13^C\]fatty acids to mice by gastric gavage. In those experiments, we observed strong ^13^C enrichment in gliomas but no ^13^C enrichment in the normal brain (except for low levels of enrichment in capillary endothelial cells). After administering \[^13^C\]glucose by gavage, ^13^C enrichment was observed in both gliomas and normal brain. It is important to note that the \[^13^C\]fatty acids and the \[^13^C\]glucose were administered in three doses over 36 hr before harvesting tissues for NanoSIMS analyses, allowing ample time for the labeled nutrients to be utilized as fuel or to be converted into other nutrients (e.g., nonessential amino acids) ([@bib37]; [@bib73]; [@bib70]). Thus, after administering ^13^C-labeled fatty acids or glucose to mice, the ^13^C in glioma cells was probably present in a variety of macromolecules (e.g., glucose, lipids, proteins, and nucleic acids).

Documenting GPIHBP1 and LPL in glioma capillaries, combined with the discovery that TRL-derived nutrients are taken up and utilized by glioma cells, opens a new chapter in glioma metabolism research ([Figure 9](#fig9){ref-type="fig"}). Laboratories that are interested in glioma metabolism have typically focused on the intrinsic metabolic properties of glioma cells and on how metabolic pathways in gliomas differ from those in normal brain ([@bib51]; [@bib28]; [@bib29]; [@bib31]; [@bib26]; [@bib76]; [@bib2]). There have been suggestions, based on indirect observations of substrate utilization, that glioma tumors are capable of utilizing fatty acids for fuel and for anabolic processes ([@bib51]; [@bib31]; [@bib55]; [@bib68]; [@bib89]). In those studies, however, the assumption was that the fatty acids probably originated from the tumor cells by *de novo* lipogenesis ([@bib30]; [@bib28]; [@bib29]). No one, as far as we are aware, had ever considered the possibility that gliomas might be capable of taking up and utilizing nutrients from LPL-mediated intravascular processing of TRLs.

![Intravascular lipolysis as a source of lipid nutrients for gliomas.\
In normal brain (left panel), LPL is produced by astrocytes, neurons, oligodendrocytes, and fibroblasts. Because GPIHBP1 is not expressed in the capillaries of the brain parenchyma, we have proposed that LPL remains within the interstitial spaces of the brain (i.e., that it has an extravascular function) ([@bib1]; [@bib87]). In gliomas (right panel), GPIHBP1 is expressed in capillary endothelial cells, allowing GPIHBP1 to capture locally produced LPL and to shuttle it to the capillary lumen. Intravascular processing of triglyceride-rich lipoproteins in gliomas provides a source of lipid nutrients for glioma cells. HSPGs, heparan sulfate proteoglycans.](elife-47178-fig9){#fig9}

In an ultrastructural study of human gliomas, [@bib79] commented that the morphology of endothelial cells in gliomas resembles that of capillary endothelial cells in peripheral tissues, with euchromatin-rich nuclei, occasional fenestrations, and numerous pinocytotic vesicles within the cytoplasm. The expression of GPIHBP1 (a hallmark of capillary endothelial cells in peripheral tissues) in gliomas provides biochemical support for the notion that glioma capillaries resemble capillaries in peripheral tissues ([@bib79]). Our electron microscopy studies confirmed that the morphological features of glioma capillaries and normal brain capillaries differ substantially.

We have relatively few insights into the molecular basis for GPIHBP1 expression in glioma capillaries. One possibility is that the absence of a blood--brain barrier in glioma capillaries ([@bib21]; [@bib85]; [@bib50]; [@bib69]) permits the exposure of endothelial cells to a paracrine factor that activates GPIHBP1 expression. Another possibility is that GPIHBP1 expression is stimulated by the expression of VEGF that is produced by glioma cells ([@bib65]; [@bib64]; [@bib13]). In our studies, VEGF increased GPIHBP1 expression in the mouse brain endothelial cell line bEnd.3.

In the past, other laboratories have reported that glioma tumor cells can transdifferentiate into endothelial cells, thereby augmenting the vascular supply to tumors ([@bib83]; [@bib66]; [@bib74]). For example, endothelial cells in human glioblastomas were reported to harbor the same genetic alterations as the tumor cells, implying that at least some of the glioblastoma endothelial cells originate from stem cells within the tumor ([@bib83]; [@bib66]). In another model ([@bib74]), a Cre recombinase (*Cre*)-loxP--controlled lentiviral vector encoding activated forms of H-Ras and Akt was injected into the hippocampus of GFAP-*Cre* p53 mice, eliciting glioblastomas. In that model, the oncogenes were expressed in the GFAP+ cells, and the resulting tumors expressed GFP, H-Ras, and Akt and the loss of p53. Some GFP+ endothelial cells were observed in tumors, implying that these endothelial cells had originated from tumor cells. Furthermore, implanting a tumor cell line (generated from tumors induced with the same lentiviral vector) into the brain of immunocompromised mice was reported to yield tumors containing GFP+ endothelial cells. In our current studies, we observed no evidence of the differentiation of glioma cells into capillary endothelial cells. The glioma cell line that we used expressed blue fluorescent protein (BFP), but we did not find BFP expression in the capillary endothelial cells of gliomas.

Mass spectrometry--based analyses of homogenized tissue extracts from mouse gliomas and normal brain tissue, along with similar analyses of tumors from human patients, suggested differences in acetate oxidation in gliomas *vs.* normal brain ([@bib55]). Although these studies of tissue extracts have been useful, they obviously cannot provide anatomical insights into metabolism. We have argued that NanoSIMS imaging studies are particularly useful when the goal is to understand metabolism at an anatomic level (cellular or subcellular) ([@bib37]). In the current studies, NanoSIMS imaging provided anatomic insights into glioma metabolism. For example, we observed TRL margination along the capillaries of gliomas but not in the capillaries of adjacent normal brain tissue. We also showed that the transport of TRL-derived nutrients across glioma capillaries and into glioma cells is rapid, occurring within 1 min, and that there is heterogeneity in nutrient uptake by different cells within the tumor. We found no uptake of TRL-derived nutrients by normal brain 1 or 15 min after the injection of \[^2^H\]TRLs and only very small amounts (confined to capillary endothelial cells) after 30 min. In addition, following the administration of \[^13^C\]glucose, we found more ^13^C enrichment in gliomas than in normal brain. As far as we are aware, our study is the first to use NanoSIMS analyses to investigate cancer metabolism *in vivo*. As we look to the future, we have little doubt that NanoSIMS imaging will be an important tool for understanding tumor metabolism, making it possible to investigate metabolic heterogeneity in tumor cells along with the metabolic properties of vascular cells, fibroblasts, and macrophages within the tumor. Nevertheless, it is important to point out that NanoSIMS imaging is not high-throughput, at least with the current instruments, and for that reason NanoSIMS imaging is best used (as in this study) to address discrete anatomic issues in metabolism. Examining large numbers of tumors or large numbers of mice would be difficult. Also, NanoSIMS imaging is very expensive.

Our studies have provided fresh insights into the uptake of lipid nutrients by gliomas, but many issues remain to be investigated. For example, in the current studies, we found numerous macrophages within gliomas, but we did not address differences in nutrient uptake by macrophages and glioma cells. In future studies, it should be possible to examine the uptake of TRL-derived nutrients into tumor cells, macrophages, and other immune cells within gliomas (by identifying specific cell types with ^15^N-labeled monoclonal antibodies or antibodies tagged with different lanthanide metals \[[@bib82]; [@bib45]; [@bib6]; [@bib46]\]). It would also be desirable to determine whether the uptake of TRL-derived nutrients in gliomas correlates with the levels of GPIHBP1 and LPL in glioma capillaries (as quantified with LPL- and GPIHBP1-specific antibodies tagged with different lanthanide metals). Finally, it would be desirable to investigate whether the presence of GPIHBP1 and LPL in glioma capillaries could be exploited for patient care. For example, it is conceivable that fluorescently labeled GPIHBP1 antibodies or DiI-labeled TRLs could guide the surgical resection of tumors. In addition, a localized injection of GPIHBP1-specific monoclonal antibodies conjugated to chemotherapeutic agents into gliomas might be useful in targeting tumor vasculature ([@bib71]). A localized injection of gold-conjugated GPIHBP1-specific monoclonal antibodies could augment the efficacy of external beam radiotherapy ([@bib34]; [@bib32]; [@bib33]).

Materials and methods {#s4}
=====================

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                                Designation                                                                   Source or reference                                              Identifiers                                                       Additional\
  (species) or resource                                                                                                                                                                                                                                         information
  -------------------------------------------- ----------------------------------------------------------------------------- ---------------------------------------------------------------- ----------------------------------------------------------------- ---------------------------------------------------------------
  Genetic reagent (*M. musculus*)              *Gpihbp1^--/--^*                                                              [@bib7]                                                          RRID: [MGI:3771172](https://scicrunch.org/resolver/MGI:3771172)   Dr. Stephen G Young (UCLA)

  Genetic reagent (*M. musculus*)              *Lpl^--/--^*MCK-hLPL                                                          [@bib49]                                                         RRID: [MGI:3624988](https://scicrunch.org/resolver/MGI:3624988)   Dr. Rudolph Zechner (Graz University)

  Genetic reagent (*M. musculus*)              ROSA^mT/mG^Pdgfb-iCre^T2^                                                     [@bib56]                                                                                                                           Dr. Holger Gerhardt (VIB KU-Leuven)

  Cell line (*M. musculus*)                    CT-2A                                                                         [@bib72]                                                                                                                           Dr. Thomas Seyfried (Boston College)

  Cell line (*M. musculus*)                    CT-2A--BFP                                                                    PMID: [24658686](https://www.ncbi.nlm.nih.gov/pubmed/24658686)                                                                     Dr. Holger Gerhardt (VIB KU-Leuven)

  Cell line (*M. musculus*)                    bEnd.3                                                                        ATCC                                                             Catalog No. CRL-2299\                                             
                                                                                                                                                                                              RRID: [CVCL_0170](https://scicrunch.org/resolver/CVCL_0170)       

  Transfected construct (lentiviral plasmid)   plenti-GLuc-IRES-EGFP                                                         Targeting Systems                                                Catalog No. GL-GFP                                                

  Antibody                                     Rat monoclonal anti-mouse GPIHBP1 (11A12)                                     [@bib8]                                                                                                                            Dr. Stephen G Young (UCLA); IHC (10 μg/ml)

  Antibody                                     Mouse monoclonal anti-human\                                                  [@bib42]                                                                                                                           Dr. Stephen G Young (UCLA); IHC (10 μg/ml)
                                               GPIHBP1 (RE3)                                                                                                                                                                                                    

  Antibody                                     Mouse monoclonal anti-human GPIHBP1 (RF4)                                     [@bib42]                                                                                                                           Dr. Stephen G Young (UCLA); IHC (10 μg/ml)

  Antibody                                     Mouse monoclonal anti-human GPIHBP1 (RG3)                                     [@bib42]                                                                                                                           Dr. Stephen G Young (UCLA); IHC (10 μg/ml)

  Antibody                                     Rabbit polyclonal anti-vWF                                                    Dako                                                             Catalog No. A0082\                                                IHC (1:200)
                                                                                                                                                                                              RRID: [AB_2315602](https://scicrunch.org/resolver/AB_2315602)     

  Antibody                                     Goat polyclonal anti-GFAP                                                     Abcam                                                            Catalog No. ab53554\                                              IHC (1:200)
                                                                                                                                                                                              RRID: [AB_880202](https://scicrunch.org/resolver/AB_880202)       

  Antibody                                     Rabbit polyclonal anti-GLUT1                                                  Millipore-Sigma                                                  Catalog No. 07--1401\                                             IHC (1:200)
                                                                                                                                                                                              RRID: [AB_1587074](https://scicrunch.org/resolver/AB_1587074)     

  Antibody                                     Rabbit polyclonal anti-CD31                                                   Abcam                                                            Catalog No. ab28364\                                              IHC (1:50)
                                                                                                                                                                                              RRID: [AB_726362](https://scicrunch.org/resolver/AB_726362)       

  Antibody                                     Rat monoclonal anti-F4/80                                                     Abcam                                                            Catalog No. ab6640\                                               IHC (10 μg/ml)
                                                                                                                                                                                              RRID: [AB_1140040](https://scicrunch.org/resolver/AB_1140040)     

  Antibody                                     Goat polyclonal anti-mouse LPL                                                [@bib62]                                                                                                                           Dr. André Bensadoun (Cornell); IHC (12 μg/ml)

  Antibody                                     Alexa Fluor 488, 568, 647 secondaries                                         ThermoFisher Scientific                                                                                                            IHC (1:500)

  Commercial assay or kit                      ImmPRESS Excel Staining Kit                                                   Vector Laboratory                                                Catalog No. MP-7602                                               

  Sequence-based reagent                       Mouse *Gpihbp1* primers                                                                                                                                                                                          5′-AGCAGGGACAGAGCACCTCT-3′ and 5′-AGACGAGCGTGATGCAGAAG-3′

  Sequence-based reagent                       Mouse *Cd31* primers                                                                                                                                                                                             5′-AACCGTATCTCCAAAGCCAGT-3′ and 5′-CCAGACGACTGGAGGAGAACT-3′

  Sequence-based reagent                       Mouse *Angpt2* primers                                                                                                                                                                                           5′-AACTCGCTCCTTCAGAAGCAGC-3′ and 5′-TTCCGCACAGTCTCTGAAGGTG-3′

  Sequence-based reagent                       Mouse *Dusp5* primers                                                                                                                                                                                            5′-TCGCCTACAGACCAGCCTATGA-3′ and 5′-TGATGTGCAGGTTGGCGAGGAA-3′

  Sequence-based reagent                       Mouse *Cxcr4* primers                                                                                                                                                                                            5′-GACTGGCATAGTCGGCAATGGA-3′ and 5′-CAAAGAGGAGGTCAGCCACTGA-3′

  Sequence-based reagent                       Mouse *Lpl* primers                                                                                                                                                                                              5′-AGGTGGACATCGGAGAACTG-3′ and 5′-TCCCTAGCACAGAAGATGACC-3′

  Sequence-based reagent                       Human *LPL* primers                                                                                                                                                                                              5′-TAGCTGGTCAGACTGGTGGA-3′ and 5′-TTCACAAATACCGCAGGTG-3′

  Recombinant DNA reagent                      ALO-D4 plasmid                                                                [@bib24]                                                                                                                           Dr. Arun Radhakrishnan (UT Southwestern)

  Chemical compound, drug                      N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (carbodiimide)   Millipore-Sigma                                                  Catalog No. 03449                                                 

  Chemical compound, drug                      Glutaraldehyde25% solution                                                    Electron Microscopy Sciences                                     Catalog No. 16220                                                 

  Chemical compound, drug                      Osmium tetroxide 4% solution                                                  Electron Microscopy Sciences                                     Catalog No. 18459                                                 

  Chemical compound, drug                      Paraformaldehyde 16% solution                                                 Electron Microscopy Sciences                                     Catalog No. 15170                                                 

  Chemical compound, drug                      EMbed 812                                                                     Electron Microscopy Sciences                                     Catalog No. 14120                                                 

  Chemical compound, drug                      Sodium cacodylate trihydrate                                                  Electron Microscopy Sciences                                     Catalog No. 12300                                                 

  Chemical compound, drug                      Uranyl acetate                                                                SPI-Chem                                                         Catalog No. 02624AB                                               

  Chemical compound, drug                      DAPI                                                                          ThermoFisher Scientific                                          Catalog No. 1306                                                  IHC (3 μg/ml)

  Chemical compound, drug                      Mouse VEGF                                                                    Millipore-Sigma                                                  Catalog No. V4512                                                 

  Software, algorithm                          LIMMA                                                                         [@bib67]                                                         RRID:\                                                            
                                                                                                                                                                                              [SCR_010943](https://scicrunch.org/resolver/SCR_010943)           

  Other                                        D-GLUCOSE (U-13C6, 99%)                                                       Cambridge Isotope Laboratories                                   Catalog No. CLM-1396-PK                                           

  Other                                        Mixed fatty acids (U-D, 96--98%)                                              Cambridge Isotope Laboratories                                   Catalog No. DLM-8572-PK                                           

  Other                                        Mixed fatty acids (13C, 98%+)                                                 Cambridge Isotope Laboratories                                   Catalog No. CLM-8455-PK                                           
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Immunohistochemical studies on human glioma specimens {#s4-1}
-----------------------------------------------------

Frozen surgical glioma specimens were obtained from the UCLA Department of Neurosurgery. Frozen autopsy control brain samples (frontal lobe, occipital lobe, and cerebellum) were obtained from the UCLA Section of Neuropathology. Samples were sectioned to 8 μm and placed on glass slides. All samples were fixed with 3% paraformaldehyde (PFA) in PBS/Ca/Mg and permeabilized in 0.2% Triton X-100 in PBS/Ca/Mg. Tissues were blocked with PBS/Ca/Mg containing 5% donkey serum and 0.2% bovine serum albumin (BSA) and incubated overnight at 4°C with one or more mouse monoclonal antibodies (mAbs) against human GPIHBP1 (RF4, RE3, RG3; 10 μg/ml) ([@bib42]), a rabbit polyclonal antibody against von Willebrand factor (vWF) (Dako; 1:200), and a goat polyclonal antibody against human glial fibrillary acidic protein (GFAP) (Abcam; 1:500). In some experiments, recombinant soluble human GPIHBP1 (50 μg) was added to the primary antibody incubation. After washing the slides, 1-hr incubations were performed with an Alexa Fluor 647--conjugated donkey anti--mouse IgG (ThermoFisher Scientific; 1:500), an Alexa Fluor 488--conjugated donkey anti--rabbit IgG (ThermoFisher Scientific; 1:500), and an Alexa Fluor 568--conjugated donkey anti--goat IgG (ThermoFisher Scientific; 1:500). DNA was stained with 4′,6-diamidino-2-phenylindole (DAPI). Images were taken with an LSM700 confocal microscope with an Axiovert 200M stand and processed with Zen 2010 software (Zeiss).

Immunoperoxidase staining was performed with the ImmPRESS Excel Staining Kit (Vector Laboratories). Endogenous peroxidase activity was quenched with BLOXALL Blocking Solution (Vector Laboratories). After incubating sections in 10% normal horse serum, sections were incubated for 1 hr with mAb RF4 (5 μg/ml), followed by a 15-min incubation with a goat anti-mouse IgG (10 μg/ml, Vector Laboratories). Slides were then incubated for 30 min with a horseradish peroxidase--conjugated horse anti--goat IgG (ImmPRESS Excel Reagent, Vector Laboratories). After washing, the slides were incubated with ImmPACT DAB EqV (Vector Laboratories) until a color change was evident (\~30 s). Finally, sections were counterstained with hematoxylin and mounted with Vectashield Mounting Media (Vector Laboratories). Images were recorded with a Nikon Eclipse E600 microscope (Plan Fluor 40×/0.50 NA or 100×/0.75 NA objectives) equipped with a DS-Fi2 camera (Nikon).

Genome dataset and gene-expression analyses {#s4-2}
-------------------------------------------

Cohorts for RNA-seq analysis were obtained from two databases: The Cancer Genome Atlas (TCGA) for tumor samples and Genotype-Tissue Expression (GTEx) for normal brain samples. Samples from TCGA (n = 157) and GTEx (n = 283) were processed with the TOIL pipeline as described ([@bib81]). A differential expression analysis of fatty acid metabolism genes was carried out with a linear model RNA-seq analysis software (LIMMA) ([@bib67]). Genes were considered differentially expressed if the *p*-values were \<0.05 and the log~2~ changes were \>twofold. A heatmap was generated with the software R ([@bib47]).

Animal procedures and glioma implantation {#s4-3}
-----------------------------------------

Mice on a C57BL/6 background expressing both the ROSA^mT/mG ^*Cre*-reporter ([@bib59]) and tamoxifen-inducible Pdgfb-iCreER^T2^ alleles ([@bib14]) were generated by breeding. In those mice, the administration of tamoxifen induces *Cre* recombinase expression in *Pdgfb*-positive cells. The recombination event results in the expression of EGFP in endothelial cells; all other cells express tdTomato. For the glioma implantation studies, mice (8--12-weeks-old) were injected intraperitoneally with tamoxifen (65 μg/g body weight, 4 injections in 2 weeks) before surgery. Mice were anesthetized with ketamine/xylazine, and a craniotomy was performed by drilling a 5‐mm hole between the lambdoid, sagittal, and coronal sutures. A blue fluorescent protein (BFP)-tagged CT‐2A glioblastoma spheroid (250-μm in diameter) ([@bib72]; [@bib60]) was injected into the cortex and sealed by cementing a glass coverslip on the skull. The CT-2A cell line was generated by Seyfried and coworkers through chemical induction with 20-methylcholanthrene in the brain of C57BL/6 mice and has been characterized extensively ([@bib72]). In other experiments, CT-2A glioblastoma spheroids were implanted into the cortex of C57BL/6 wild-type mice and *Gpihbp1*^--/--^ mice ([@bib7]). Those procedures were performed as described previously ([@bib75]).

Immunohistochemical studies on mouse gliomas {#s4-4}
--------------------------------------------

Mice harboring BFP-expressing CT-2A gliomas ([@bib72]; [@bib60]) were anesthetized with ketamine/xylazine and then injected intravenously (*via* the tail vein) with 100 μg of an Alexa Fluor 647--conjugated antibody against mouse GPIHBP1 (11A12) ([@bib8]). After 1 min, the mice were perfused through the heart with 15 ml of PBS, followed by 10 ml of 2% PFA in PBS. Brain and glioma tissues were harvested and fixed overnight in 4% PFA. Tissue sections (200-μm-thick) were prepared with a vibratome. For immunofluorescence microscopy studies, the sections were fixed with 4% PFA in PBS and blocked and permeabilized in TNBT (0.1 M Tris, pH 7.4, 150 mM NaCl, 0.5% blocking reagent from Perkin Elmer, 0.5% Triton X‐100) for 4 hr at room temperature. Tissues were incubated with an antibody against GLUT1 (Millipore; 1:200) diluted in TNBT buffer overnight at 4°C, washed in TNT buffer (0.1 M Tris pH 7.4; 150 mM NaCl, 0.5% Triton X‐100) and incubated with an Alexa Fluor 488--conjugated donkey anti--rabbit IgG (ThermoFisher Scientific; 1:200). Tissues were washed and mounted in fluorescent mounting medium (Dako). Images were obtained with a Leica TCS SP8 confocal microscope.

For the analysis of tissues from mice that were not injected with anti-GPIHBP1 antibodies, tissues were embedded in OCT medium, and 10-µm sections were cut with a cryostat. Sections were fixed with 3% PFA in PBS/Ca/Mg, permeabilized with 0.2% Triton X-100 in PBS/Ca/Mg, and blocked with PBS/Ca/Mg containing 5% donkey serum and 0.2% BSA. Tissue sections were incubated overnight at 4°C with a rabbit antibody against CD31 (Abcam; 1:50), a goat antibody against mouse LPL (12 μg/ml) ([@bib62]), an Alexa Fluor 488--conjugated antibody against F4/80, or an Alexa Fluor 647--conjugated antibody against mouse GPIHBP1 (11A12, 10 μg/ml). After removing non-bound antibodies and washing the sections, unlabeled primary antibodies were detected with an Alexa Fluor 488--conjugated donkey anti--rabbit IgG (ThermoFisher Scientific; 1:500) or an Alexa Fluor 568--conjugated donkey ant--goat IgG (ThermoFisher Scientific; 1:500). DNA was stained with DAPI, and tissues were mounted with ProLong Gold mounting media (ThermoFisher Scientific). Images were recorded on an LSM 800 confocal microscope (Zeiss).

Immunocytochemistry studies on mouse peritoneal macrophages {#s4-5}
-----------------------------------------------------------

Macrophages were collected by peritoneal lavage of C57BL/6 wild-type and *Lpl^--/--^*MCK-hLPL mice. Cells were centrifuged at 400 × g for 5 min at 4°C, washed with 5 ml of red blood cell lysing buffer (Sigma) for 5 min, washed twice with cold PBS, and then plated onto FBS-coated Petri dishes. Cells were cultured overnight in macrophage medium (Dulbecco Modified Eagle Medium with 10% FBS, 1% glutamine, and 1% sodium pyruvate). On the next day, macrophages were lifted with cold PBS containing 5 mM EDTA for 30 min at 4°C. Cells were then plated onto poly-D-lysine--coated glass coverslips (75,000 cells/coverslip) and incubated overnight in macrophage media. On the following day, the cells were washed three times for 10 min in PBS/Ca/Mg containing 0.2% BSA and then incubated with Alexa Fluor 568--labeled ALO-D4 (a modified cytolysin that binds to 'accessible cholesterol' in the plasma membrane) ([@bib17]; [@bib16]; [@bib24]) for 2 hr at 4°C. Samples were washed three times for 1 min with PBS/Ca/Mg, fixed with 3% PFA in PBS/Ca/Mg, permeabilized with 0.2% Triton X-100 in PBS/Ca/Mg, and blocked with PBS/Ca/Mg containing 5% donkey serum and 0.2% BSA. Cells were then incubated with a goat antibody against mouse LPL (12 μg/ml) ([@bib62]) for 1 hr at room temperature followed by a 30-min incubation with an Alexa Fluor 647--labeled donkey anti--goat IgG (ThermoFisher Scientific; 1:500). DNA was stained with DAPI, and coverslips were mounted onto glass slides in ProLong Gold mounting media (ThermoFisher Scientific). Images were recorded with a Zeiss LSM700 confocal microscope.

Administration of \[^13^C\]fatty acids, \[^13^C\]glucose, and \[^2^H\]TRLs to mice {#s4-6}
----------------------------------------------------------------------------------

C57BL/6 mice with CT-2A gliomas (of three-week duration) were given 80 μl of \[^13^C\]fatty acids (\~1 mg/μl; Cambridge Isotope Laboratories) or 80 μl of \[^13^C\]glucose (3 mg/kg body weight; Cambridge Isotope Laboratories) by oral gavage every 12 hr for 36 hr (three doses). To study TRL metabolism, mice were injected intravenously with a single bolus of \[^2^H\]TRLs (40 μg triglycerides in 100 µl) via the tail vein. The \[^2^H\]TRLs were isolated from the plasma of *Gpihbp1*^--/--^ mice after administering deuterated fatty acids by gastric gavage ([@bib37]). After allowing the \[^2^H\]TRLs to circulate for 1 min or 30 min, the mice were perfused through the heart with 15 ml of ice-cold PBS/Ca/Mg at 3 ml/min (10 ml though the left ventricle and 5 ml through the right ventricle). Next, the mice were perfusion-fixed through the left ventricle with 10 ml of ice-cold 4% N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride ('carbodiimide;' Sigma-Aldrich) (mass/vol) and 0.4% glutaraldehyde (Electron Microscopy Sciences) (vol/vol) in 0.1 M phosphate buffer. The heart, brain, and glioma tumors were collected and placed in 0.1 M phosphate buffer containing 4% carbodiimide and 2.5% glutaraldehyde for 2 hr at 4°C. Tissues were cut into 1-mm^3^ pieces and fixed overnight in 2.5% glutaraldehyde, 3.7% PFA, and 2.1% sucrose in 0.1 M sodium cacodylate (pH 7.4).

Preparation of tissue sections for NanoSIMS imaging and electron microscopy {#s4-7}
---------------------------------------------------------------------------

After fixation, 1-mm^3^ pieces of tissue were rinsed three times (10 min each) in 0.1 M sodium cacodylate buffer (pH 7.4) and fixed with 2% OsO~4~ (Electron Microscopy Sciences) in 0.1 M sodium cacodylate on ice for 90 min. The samples were rinsed three times (10 min each) with distilled water and stained overnight with 2% uranyl acetate at 4°C. On the following day, the samples were rinsed three times for 10 min each with distilled water and then dehydrated with increasing amounts of ethanol (30%, 50%, 70%, 85%, 95%, and 100%; 3 × 10 min) before infiltration with Embed812 resin (Electron Microscopy Sciences) diluted in acetone (33% for 2 hr; 66% overnight; 100% for 3 hr). The samples were embedded in polyethylene molds (Electron Microscopy Sciences) with fresh resin and polymerized in a vacuum oven at 65°C for 48 hr. The polymerized blocks were then removed from the molds, trimmed, and sectioned.

For transmission electron microscopy, 65-nm sections were cut and collected on freshly glow-discharged copper grids (Ted Pella) that were coated with formvar and carbon. Sections were then stained with Reynold's lead citrate solution for 10 min. Images were acquired with an FEI T12 transmission electron microscope set to 120 kV accelerating voltage and a Gatan 2K × 2K digital camera (Electron Imaging Center).

For NanoSIMS analyses, 500-nm sections were cut with a Leica UC6 ultramicrotome and collected on silicon wafers. Sections of tissue were coated with \~5 nm of platinum and analyzed with NanoSIMS 50L or NanoSIMS 50 instruments (CAMECA). Samples were scanned with a 16-KeV ^133^Cs^+^ beam, and secondary electrons (SEs) and secondary ions (^1^H^--^, ^2^H^--^, ^12^C^--^, ^13^C^--^, ^12^C^14^N^--^) were collected. A 50 × 50-μm region of the section was pre-sputtered with a ∼1.2-nA beam current (primary aperture D1 = 1) to reach a dose of \~1 × 10^17^ ions/cm^2^ to remove the platinum coating and implant ^133^Cs^+^ in order to ensure a steady state of secondary ion release. A ∼40 × 40-μm region was imaged with an ∼3-pA beam current (primary aperture D1 = 2) and a dwell time of \~10 ms/pixel per frame for multiple frames. Both 256 × 256--pixel and 512 × 512--pixel images were obtained. Images were prepared using the OpenMIMS plugin in ImageJ. For image quantification, ^2^H/^1^H and ^13^C/^12^C ratios in the regions of interests were calculated with the OpenMIMS plugin and processed by GraphPad Prism 7.0.

Tumor studies in wild-type and *Gpihbp1*-deficient mice {#s4-8}
-------------------------------------------------------

Three-month-old C57BL/6 wild-type (five females, six males) and *Gpihbp1^--/--^* mice (six females, five males) were injected intracranially with CT-2A glioma cells stably expressing a *Gaussia* luciferase reporter gene (4 × 10^5^ cells/mouse). Cells were injected 1 mm posterior and 2 mm lateral to the bregma at a depth of 2 mm. Tumor burden was monitored every three days by measuring *Gaussia* luciferase in the blood ([@bib54]; [@bib77]). Mice were weighed at weekly intervals and were euthanized when they lost \>20% of their body weight. After the mice were euthanized, their tumors and brains were weighed. All studies were approved by UCLA's Animal Research Committee.

*Gaussia* luciferase measurements {#s4-9}
---------------------------------

To measure the levels of secreted *Gaussia* luciferase (sGluc), blood was obtained from the tail vein of mice and mixed with 50 mM EDTA to prevent coagulation. 5 μl of blood was transferred to a 96-well plate, and sGluc activity was measured by chemiluminescence after injecting 100 μl of 100 μM coelentarazine (Nanolight) ([@bib54]; [@bib77]). Data were plotted as relative light units (RLU).

Quantifying mouse and human transcripts by qRT-PCR {#s4-10}
--------------------------------------------------

C57BL/6 wild-type mice and *Lpl^--/--^*MCK-hLPL mice were anesthetized with isoflurane and perfused with PBS. Heart, brown adipose tissue (BAT), and quadricep were harvested and flash-frozen in liquid nitrogen. RNA was isolated with TRI reagent (Molecular Research), and quantitative (q)RT-PCR measurements were performed in triplicate with a 7900HT Fast real-time PCR system (Applied Biosystems). Gene expression was calculated with a comparative CT method and normalized to levels of cyclophilin A expression. Primers for mouse *Gpihbp1*, mouse *Lpl*, and human *LPL* are described in the \'Key Resources Table\'.

VEGF treatment of brain endothelial cells {#s4-11}
-----------------------------------------

Mouse brain microvascular endothelial cells (bEnd.3; ATCC \#CRL-2299) were plated into 6-well plates and grown in DMEM media containing 10% FBS, 1% glutamine, and 1% sodium pyruvate overnight. On the next day, cells were rinsed with PBS and incubated in medium containing recombinant mouse VEGF (100 ng/ml; Sigma) for another 24 hr. RNA was isolated with TRI reagent (Molecular Research), and qRT-PCR measurements were performed in triplicate with a 7900HT Fast real-time PCR system (Applied Biosystems). Gene expression was calculated with a comparative CT method and normalized to cyclophilin A expression. Primers for mouse *Gpihbp1*, *Cd31*, *Angpt2*, *Cxcr4*, and *Dusp5* are described in the \'Key Resources Table\'.

Cell lines {#s4-12}
----------

CT-2A cells were obtained originally from the Seyfried laboratory and have been extensively tested and characterized ([@bib72]). These cells also robustly expressed GFAP. The bEnd.3 cells were obtained from ATCC with a proper 'certificate of analysis'. All cell lines were negative for mycoplasma contamination.

Statistics {#s4-13}
----------

Statistical analyses of data were performed with GraphPad Prism 7.0 software. All data are shown as the means ± standard deviations. Differences were assessed using a Student's *t*-test with Welch's correction.

Study approval {#s4-14}
--------------

All tissue samples from patients were obtained after informed consent and with approval from the UCLA Institutional Review Board (IRB; protocol 10--000655). Animal housing and experimental protocols were approved by UCLA's Animal Research Committee (ARC; 2004-125-51, 2016--005) and the Institutional Animal Care and Research Advisory Committee of the KU Leuven (085/2016). The animals were housed in an AAALAC (Association for Assessment and Accreditation of Laboratory Animal Care International)-approved facility and cared for according to guidelines established by UCLA's Animal Research Committee. The mice were fed a chow diet and housed in a barrier facility with a 12 hr light-dark cycle.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"GPIHBP1 expression in gliomas promotes utilization of lipoprotein-derived nutrients\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Harry Dietz as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Rodney Elwood Infante (Reviewer \#1); Rolf Brekken (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

This well-presented study proposes an intriguing role for GPIHBP1-mediated LPL activity in the context of brain tumors. The authors show that GPIHBP1 is expressed in capillary endothelial cells of gliomas, but not in normal brains. Using NanoSIMS technology, at which the members of this group are experts, they show that GPIHBP1\'s interaction with LPL allows for gliomas to have increased triglyceride-rich lipoprotein uptake and utilization. They postulate that gliomas use this system as a source of nutrients for their growth. All reviewers agreed that the study was well-executed and that the findings were potentially significant, but all of them raised the same concern about whether GPIHBP1 was important for glioma development or progression. They welcomed a revised submission which addressed this concern, along with answers to some additional questions.

Essential revisions:

1\) Please compare the tumor growth, number, and size in WT and GPIHBP1-deficient mice. If gliomas grow well in the absence of GPIHBP1, is this due to expression of Glut-1 on the vasculature in gliomas in GPIHBP1-deficient mice?

2\) Provide some additional insight into the mechanism of increased GPIHBP1 expression in glioma associated vasculature. What is known about GPIHBP1 expression in other tissues and are any factors known to be associated with its expression?

3\) Is it possible that the tail-vein injected Alexa Fluor 647-labeled GPIHBP1 antibody has access to gliomas and not to the normal brain tissue because of an impaired blood brain barrier in the case of the gliomas? Although there are figures where GPIHBP1 was stained after fixation, it is always done on slides with only normal tissue. An experiment similar to what is done for Glut1 in Figure 4 should be done for GPIHBP1 -- slides containing both glioma and normal tissue where both GLUT1 and GPIHBP1 antibodies are used after fixation.

4\) Does the expression of LPL affect the expression of GPIHBP1 in gliomas? The LPL knockout mouse model was used for IHC for normal brain tissue, but not for the glioma model (Figure 5---figure supplement 5).

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"GPIHBP1 expression in gliomas promotes utilization of lipoprotein-derived nutrients\" for further consideration at *eLife*. Your revised article has been favorably evaluated by Harry Dietz (Senior Editor) and a Reviewing Editor.

The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:

The authors have addressed most of the points raised by the reviewers by providing new supporting data and reframing parts of the manuscript. The reviewers all agreed that this revised manuscript will be suitable for publication once one lingering concern is addressed. The authors clearly show that GPIHBP1 is not critical to glioma progression, at least in implant models (Figure 8---figure supplement 4), and provide a satisfactory explanation for why this may be so. Consequently, statements implying that GPIHBP1 expression in gliomas is important for tumor growth should be toned down or removed (e.g. in the impact statement and the last sentence of the Abstract). The authors may instead choose to highlight how the stark difference in GPIHBP1 expression in normal versus glioma capillaries could be utilized as a therapeutic tool (as they describe in the last paragraph of the Discussion).

10.7554/eLife.47178.039

Author response

> Summary:
>
> This well-presented study proposes an intriguing role for GPIHBP1-mediated LPL activity in the context of brain tumors. The authors show that GPIHBP1 is expressed in capillary endothelial cells of gliomas, but not in normal brains. Using NanoSIMS technology, at which the members of this group are experts, they show that GPIHBP1\'s interaction with LPL allows for gliomas to have increased triglyceride-rich lipoprotein uptake and utilization. They postulate that gliomas use this system as a source of nutrients for their growth. All reviewers agreed that the study was well-executed and that the findings were potentially significant, but all of them raised the same concern about whether GPIHBP1 was important for glioma development or progression. They welcomed a revised submission which addressed this concern, along with answers to some additional questions.

We thank the reviewers and editors for their kind and generous comments about our manuscript. Over the past month, we have performed additional experiments in order to respond to the criticisms of the reviewers. In the revised manuscript, we believe that we have addressed all of the reviewers' concerns. In addition, we added an additional experiment in which we performed NanoSIMS imaging of heart and brain of wild-type and *Gpihbp1*-deficient mice 15 min following the injection of \[^2^H\]TRLs (Figure 7---figure supplement 2).

> Essential revisions:
>
> 1\) Please compare the tumor growth, number, and size in WT and GPIHBP1-deficient mice. If gliomas grow well in the absence of GPIHBP1, is this due to expression of Glut-1 on the vasculature in gliomas in GPIHBP1-deficient mice?

We thank the reviewers for this suggestion. We injected CT-2A glioma cells that had been stably transfected with a Gaussia luciferase reporter (1, 2) into the brain of wild-type (n = 11) and *Gpihbp1*-deficient mice (n = 11). We monitored tumor mass by measuring the level of luciferase in the blood over a span of 3 weeks. In addition, we measured body weight at regular intervals, euthanizing mice when they lost more than 20% of their initial body weight. Finally, we weighed tumors after euthanizing the mice. We observed no statistically significant differences in tumor growth, tumor size, or survival between wild-type and *Gpihbp1*^--/--^ mice. In the revised manuscript, we have included a supplemental figure showing these data (Figure 8---figure supplement 4).

The fact that we did not find significantly smaller tumors in *Gpihbp1*^--/--^ mice was not surprising. Despite markedly elevated plasma triglyceride levels and inefficient processing of lipoproteins, *Gpihbp1*^--/--^ mice appear healthy and have normal cardiac function. The heart normally uses large amounts of lipoprotein-derived triglycerides for fuel but manages to function normally in *Gpihbp1*^--/--^ mice, likely because of the heart's ability to compensate by utilizing glucose and/or albumin-bound fatty acids. Given those observations, we suspected that the gliomas in *Gpihbp1*^--/--^ mice would be able to grow fairly normally---as a result of their ability to use glucose and/or glucose-derived metabolites as fuel. When \[^13^C\]glucose was administered to wild-type mice, NanoSIMS imaging revealed substantial ^13^C enrichment in tumors. Also, our paper demonstrated that glioma capillary endothelial cells express GLUT1. In the revised manuscript, we show additional studies that document GLUT1 expression in glioma capillaries of wild-type and *Gpihbp1*^--/--^ mice (Figure 4---figure supplement 4).

Our studies provide strong support for the notion that GPIHBP1 expression in glioma capillaries facilitates uptake of lipoprotein-derived nutrients by tumor cells in wild-type mice. In the revised manuscript, we report that glioma tumors can grow in the absence of GPIHBP1, likely a result of the same sort of compensatory mechanisms that allow normal heart function in *Gpihbp1*-deficient mice.

> 2\) Provide some additional insight into the mechanism of increased GPIHBP1 expression in glioma associated vasculature. What is known about GPIHBP1 expression in other tissues and are any factors known to be associated with its expression?

Thank you; this is an important issue. Thus far, mechanisms underlying GPIHBP1 expression in capillary endothelial cells are unclear. However, Chiu and coworkers recently reported that GPIHBP1 expression in cultured rat aortic endothelial cells can be induced by VEGF (3).

Over the past month, we have tested GPIHBP1 expression in the mouse brain endothelial cell line bEnd.3. We found that treating those cells with VEGF increased *Gpihbp1* transcripts substantially. We have included those studies as a supplementary figure in the revised manuscript (Figure 3---figure supplement 3).

The induction of *Gpihbp1* expression by VEGF could potentially explain why GPIHBP1 is expressed in glioma capillaries in vivo. Glioma cells are known to produce VEGF (4--6).

In terms of understanding *Gpihbp1* expression, we would also draw the reviewers' attention to our recent discovery of a *Gpihbp1* enhancer element, located ∼3.6 kb upstream from exon 1 of mouse *Gpihbp1* (7). Mice with a deletion of this enhancer had a \~90% decrease in *Gpihbp1* expression in capillaries of the liver but only a \~50% decrease in *Gpihbp1* transcripts in capillaries of heart and brown adipose tissue. The impact of the enhancer deletion on *Gpihbp1* expression was insufficient to elicit hypertriglyceridemia. Our publication provided the first insight into DNA sequences regulating *Gpihbp1* expression.

> 3\) Is it possible that the tail-vein injected Alexa Fluor 647-labeled GPIHBP1 antibody has access to gliomas and not to the normal brain tissue because of an impaired blood brain barrier in the case of the gliomas? Although there are figures where GPIHBP1 was stained after fixation, it is always done on slides with only normal tissue. An experiment similar to what is done for Glut1 in Figure 4 should be done for GPIHBP1 -- slides containing both glioma and normal tissue where both GLUT1 and GPIHBP1 antibodies are used after fixation.

We agree that the blood--brain barrier of gliomas can be leaky. However, there is no reason to believe that intravenously injected Alexa Fluor 647--labeled GPIHBP1 antibody would have greater access to glioma vasculature, simply because GPIHBP1 is located on the luminal surface of capillary endothelial cells. Thus, the injected antibodies would not need to cross the blood--brain barrier to bind to GPIHBP1. To further address the reviewer's concerns, we performed staining of glioma and normal brain tissue with antibodies against GPIHBP1 and GLUT1 *after tissue fixation* (Figure 4---figure supplement 2). GPIHBP1 was present in endothelial cells of tumors but not in normal brain; GLUT1 was present in endothelial cells in both tumor and adjacent normal brain.

> 4\) Does the expression of LPL affect the expression of GPIHBP1 in gliomas? The LPL knockout mouse model was used for IHC for normal brain tissue, but not for the glioma model (Figure 5---figure supplement 5).

We have no evidence that the expression of LPL influences the expression of GPIHBP1. GPIHBP1 and LPL in peripheral tissues are produced in different cell types---GPIHBP1 in endothelial cells and LPL in parenchymal cells. We no longer have access to adult LPL knockout mice. However, to address the reviewers' concern, we examined transcript levels in archived tissue biopsies (heart, brown adipose tissue, skeletal muscle) from wild-type and *Lpl^--/--^*MCK-hLPL mice. The MCK-hLPL transgene is expressed at high levels in skeletal muscle and at much lower levels in the heart; the transgene is not expressed in brown adipose tissue. In these studies, our goal was to determine whether *Gpihbp1* expression in skeletal muscle or heart would be altered by overexpression of human LPL. In heart and brown adipose tissue, *Gpihbp1* expression levels were similar in wild-type mice and the *Lpl^--/--^*MCK-hLPL mice. In skeletal muscle, where hLPL levels are very high, *Gpihbp1* expression was also similar in wild-type mice and the *Lpl^--/--^*MCK-hLPL mice. Thus, overexpression of LPL did not influence *Gpihbp1* expression (Figure 5---figure supplement 8).

We would add that we recently documented normal plasma GPIHBP1 levels (a measurement that reflects GPIHBP1 expression in capillaries) in a human subject who was homozygous for a nonsense mutation in *LPL* (8), consistent with the notion that the amount of LPL expression does not affect GPIHBP1 expression in capillary endothelial cells.

In light of these findings, there is little reason to believe that the modest amounts of LPL expression in the brain would influence GPIHBP1 expression in gliomas.
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\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

> The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:
>
> The authors have addressed most of the points raised by the reviewers by providing new supporting data and reframing parts of the manuscript. The reviewers all agreed that this revised manuscript will be suitable for publication once one lingering concern is addressed. The authors clearly show that GPIHBP1 is not critical to glioma progression, at least in implant models (Figure 8---figure supplement 4), and provide a satisfactory explanation for why this may be so. Consequently, statements implying that GPIHBP1 expression in gliomas is important for tumor growth should be toned down or removed (e.g. in the impact statement and the last sentence of the Abstract). The authors may instead choose to highlight how the stark difference in GPIHBP1 expression in normal versus glioma capillaries could be utilized as a therapeutic tool (as they describe in the last paragraph of the Discussion).

In the current revision, we have removed all statements implying the possibility that GPIHBP1 could be relevant to the growth of gliomas, including in the "impact statement." Instead, we simply state that GPIHBP1 expression facilitates TRL processing in gliomas, providing a source of lipid nutrients for glioma cells.
